Journal
MULTIPLE SCLEROSIS JOURNAL
Volume 28, Issue 7, Pages 1101-1111Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/13524585211049397
Keywords
Multiple sclerosis; cognition; SDMT; relapse; neuropsychological tests; psychometrics
Categories
Funding
- National MS Society [NMSS RG 5195A4/1]
Ask authors/readers for more resources
The study suggests that an SDMT score change of 8 or more points offers the best balance of discriminatory power and external validity for estimating cognitive decline in individual patients. This methodology could be useful for identifying meaningful cognitive decline in both clinical management and clinical trial outcomes.
Background: The Symbol Digit Modalities Test (SDMT) is increasingly utilized in clinical trials. A SDMT score change of 4 points is considered clinically important, based on association with employment anchors. Optimal thresholds for statistically reliable SDMT changes, accounting for test reliability and measurement error, are yet to be applied to individual cases. Objective: The aim of this study was to derive a statistically reliable marker of individual change on the SDMT. Methods: This prospective, case-control study enrolled 166 patients with multiple sclerosis (MS). SDMT scores at baseline, relapse, and 3-month follow-up were compared between relapsing and stable patient groups. Using data from the stable group and three previously published studies, candidate thresholds for reliable decline were calculated and validated against other tests and a clinically meaningful anchor-cognitive relapse. Results: Candidate thresholds for reliable decline at the 80% confidence level varied between 6 and 11 points. An SDMT change of 8 or more raw score points was deemed to offer the best balance of discriminatory power and external validity for estimating cognitive decline. Conclusion: This study illustrates the feasibility and usefulness of reliable change methodology for identifying statistically meaningful cognitive decline that could be implemented to identify change in individual patients, for both clinical management and clinical trial outcomes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available